ABIONYX Pharma

Report Publication Announcement • Apr 23, 2018

Press release

Publication of 2017 Registration Document

Toulouse, FRANCE, Ann Arbor, UNITED-STATES, April 23, 2018 – Cerenis Therapeutics (FR0012616852 – CEREN – Eligible PEA PME), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces the publication of its 2017 Registration Document under reference number R.18-022.

The document is available, free of charge, at the Company's headquarters(265, rue de la Découverte, 31670 Labège), and under digital version on the French Market Authorities' website (www.amf-france.org) and also on Cerenis' one (www.cerenis.com).

The following documents are integrated in the 2017 Registration Document:

• Report on corporate governance ;
• Description of the share buy-back program ;
• 2017 Financial Annual Report.

Financial calendar: Cash position and activity update for Q2: July 26, 2018

About Cerenis: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL and other therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particlesto treat atherosclerosis and associated metabolic diseasesincluding Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

Cerenisis well positioned to become one of the leadersin thisinnovative lipid metabolism therapeutic market, with a broad portfolio of programs in development.

Contacts:

Cerenis

Jean-Louis Dasseux CEO info@cerenis.com +33 (0)5 62 24 09 49

NewCap

Investors relations Emmanuel Huynh / Louis-Victor Delouvrier cerenis@newcap.eu +33 (0)1 44 71 98 53

NewCap

Media relations Nicolas Merigeau cerenis@newcap.eu +33 (0)1 44 71 94 98